Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

The wonderland of neuronal nicotinic acetylcholine receptors.

Bertrand D, Terry AV Jr.

Biochem Pharmacol. 2018 May;151:214-225. doi: 10.1016/j.bcp.2017.12.008. Epub 2017 Dec 14. Review.

PMID:
29248596
3.

Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies.

Pandya AA, Yakel JL.

Biochem Pharmacol. 2013 Oct 15;86(8):1054-62. doi: 10.1016/j.bcp.2013.05.018. Epub 2013 May 31. Review.

4.

Nicotinic acetylcholine receptors as drug targets.

Hogg RC, Bertrand D.

Curr Drug Targets CNS Neurol Disord. 2004 Apr;3(2):123-30. Review.

PMID:
15078187
5.

Allosteric modulation of nicotinic acetylcholine receptors.

Chatzidaki A, Millar NS.

Biochem Pharmacol. 2015 Oct 15;97(4):408-417. doi: 10.1016/j.bcp.2015.07.028. Epub 2015 Jul 29. Review.

PMID:
26231943
6.

Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors.

Pandya A, Yakel JL.

Biochem Pharmacol. 2011 Oct 15;82(8):952-8. doi: 10.1016/j.bcp.2011.04.020. Epub 2011 May 7. Review.

7.

Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.

Verma S, Kumar A, Tripathi T, Kumar A.

J Pharm Pharmacol. 2018 Aug;70(8):985-993. doi: 10.1111/jphp.12919. Epub 2018 Apr 16. Review.

PMID:
29663387
8.

Designing selective modulators for the nicotinic receptor subtypes: challenges and opportunities.

Manetti D, Bellucci C, Chiaramonte N, Dei S, Teodori E, Romanelli MN.

Future Med Chem. 2018 Feb 1;10(4):433-459. doi: 10.4155/fmc-2017-0169. Epub 2018 Feb 16. Review.

PMID:
29451400
9.

Physical and virtual screening methods for marine toxins and drug discovery targeting nicotinic acetylcholine receptors.

Molgó J, Aráoz R, Benoit E, Iorga BI.

Expert Opin Drug Discov. 2013 Oct;8(10):1203-23. doi: 10.1517/17460441.2013.822365. Epub 2013 Aug 6. Review.

PMID:
23919818
10.
11.

In vitro and in vivo neuronal nicotinic receptor properties of (+)- and (-)-pyrido[3,4]homotropane [(+)- and (-)-PHT]: (+)-PHT is a potent and selective full agonist at α6β2 containing neuronal nicotinic acetylcholine receptors.

Carroll FI, Navarro HA, Mascarella SW, Castro AH, Luetje CW, Wageman CR, Marks MJ, Jackson A, Damaj MI.

ACS Chem Neurosci. 2015 Jun 17;6(6):920-6. doi: 10.1021/acschemneuro.5b00077. Epub 2015 Apr 30.

13.

Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors.

Hogg RC, Bertrand D.

Biochem Pharmacol. 2007 Feb 15;73(4):459-68. Epub 2006 Sep 18. Review.

PMID:
16979139
14.

α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia.

Ishikawa M, Hashimoto K.

Curr Pharm Des. 2011;17(2):121-9. Review.

PMID:
21355839
15.

Contrasting properties of α7-selective orthosteric and allosteric agonists examined on native nicotinic acetylcholine receptors.

Gill JK, Chatzidaki A, Ursu D, Sher E, Millar NS.

PLoS One. 2013;8(1):e55047. doi: 10.1371/journal.pone.0055047. Epub 2013 Jan 29.

16.

Discovery and development of α7 nicotinic acetylcholine receptor modulators.

Mazurov AA, Speake JD, Yohannes D.

J Med Chem. 2011 Dec 8;54(23):7943-61. doi: 10.1021/jm2007672. Epub 2011 Sep 29. Review. No abstract available.

PMID:
21919481
17.

Nicotinic receptors, allosteric proteins and medicine.

Changeux JP, Taly A.

Trends Mol Med. 2008 Mar;14(3):93-102. doi: 10.1016/j.molmed.2008.01.001. Epub 2008 Feb 11.

PMID:
18262468
18.

alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex.

Livingstone PD, Srinivasan J, Kew JN, Dawson LA, Gotti C, Moretti M, Shoaib M, Wonnacott S.

Eur J Neurosci. 2009 Feb;29(3):539-50. doi: 10.1111/j.1460-9568.2009.06613.x. Epub 2009 Jan 28.

PMID:
19187266
19.

Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.

Potasiewicz A, Nikiforuk A, Hołuj M, Popik P.

J Psychopharmacol. 2017 Feb;31(2):260-271. doi: 10.1177/0269881116675509. Epub 2016 Nov 15.

PMID:
28168926
20.

Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.

Grupe M, Grunnet M, Bastlund JF, Jensen AA.

Basic Clin Pharmacol Toxicol. 2015 Mar;116(3):187-200. doi: 10.1111/bcpt.12361. Epub 2014 Dec 29. Review.

Supplemental Content

Support Center